Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.
This study is testing a new medication called PM54 in patients with advanced solid tumors that have not responded to standard treatments. Researchers want to find the safest and most effective dose of this new drug.
You might be able to join if you are 18 or older, can handle normal daily activities, and have a confirmed advanced solid tumor with no standard treatment options left. However, you cannot join if you have uncontrolled high blood pressure or significant heart valve disease.
You will receive the study medication through a vein (intravenously) while doctors closely monitor your health, check for side effects, and see how your tumor responds to the treatment.
This study is currently recruiting participants at locations in San Antonio, Texas in the United States, as well as in Anderlecht, Belgium and Madrid, Spain.
- 1Testing a new medication called PM54 for advanced solid tumors
- 2Finding the safest and most effective dose for future treatments
- 3Currently recruiting patients in the US, Belgium, and Spain
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.